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Abstract
Background: Missense mutations and multiplications of the α-synuclein gene cause autosomal
dominant familial Parkinson's disease (PD). α-Synuclein protein is also a major component of Lewy
bodies, the hallmark pathological inclusions of PD. Therefore, α-synuclein plays an important role
in the pathogenesis of familial and sporadic PD. To model α-synuclein-linked disease in vivo,
transgenic mouse models have been developed that express wild-type or mutant human α-
synuclein from a variety of neuronal-selective heterologous promoter elements. These models
exhibit a variety of behavioral and neuropathological features resembling some aspects of PD.
However, an important deficiency of these models is the observed lack of robust or progressive
nigrostriatal dopaminergic neuronal degeneration that is characteristic of PD.
Results: We have developed conditional α-synuclein transgenic mice that can express A53T, E46K
or C-terminally truncated (1–119) human α-synuclein pathological variants from the endogenous
murine ROSA26 promoter in a Cre recombinase-dependent manner. Using these mice, we have
evaluated the expression of these α-synuclein variants on the integrity and viability of nigral
dopaminergic neurons with age. Expression of A53T α-synuclein or truncated αSyn119 selectively
in nigrostriatal pathway dopaminergic neurons for up to 12 months fails to precipitate
dopaminergic neuronal loss in these mice. However, αSyn119 expression in nigral dopaminergic
neurons for up to 12 months causes a marked reduction in the levels of striatal dopamine and its
metabolites together with other subtle neurochemical alterations.
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Conclusion: We have developed and evaluated novel conditional α-synuclein transgenic mice with
transgene expression directed selectively to nigrostriatal dopaminergic neurons as a potential new
mouse model of PD. Our data support the pathophysiological relevance of C-terminally truncated
α-synuclein species in vivo. The expression of αSyn119 in the mouse nigrostriatal dopaminergic
pathway may provide a useful model of striatal dopamine depletion and could potentially provide a
presymptomatic model of PD perhaps representative of the earliest derangements in dopaminergic
neuronal function observed prior to neuronal loss. These conditional α-synuclein transgenic mice
provide novel tools for evaluating and dissecting the age-related effects of α-synuclein pathological
variants on the function of the nigrostriatal dopaminergic pathway or other specific neuronal
populations.
Background
Parkinson's disease (PD) is the most common neurode-
generative movement disorder characterized by the cardi-
nal symptoms of muscular rigidity, resting tremor and
bradykinesia [1,2]. Underlying these motor deficits is the
progressive loss of dopaminergic neurons of the substan-
tia nigra pars compacta in addition to several other neuro-
nal populations, the corresponding reduction of striatal
dopamine levels, and the appearance of Lewy bodies and
Lewy neurites in surviving neurons of the brainstem [1-3].
Lewy bodies are round eosinophilic intracytoplasmic pro-
teinaceous inclusions composed of filamentous material,
a major component of which is the protein α-synuclein
[4]. Missense mutations (A30P, E46K and A53T) and mul-
tiplications of the α-synuclein gene cause rare autosomal
dominant familial forms of PD that often manifest disease
in some families with an extended clinical and pathologi-
cal spectrum resembling dementia with Lewy bodies
(DLB) [5-9]. Thus, α-synuclein most likely plays a key role
in the pathogenesis of familial and sporadic PD in addi-
tion to DLB.
It is not clear how mutations in α-synuclein, or increased
levels of the wild-type α-synuclein protein due to gene
multiplications, precipitate the demise of nigral dopamin-
ergic neurons in familial PD. How α-synuclein contrib-
utes to the pathogenesis of the more common sporadic
form of PD is also not known. It has been postulated that
post-translational modifications of normal α-synuclein,
including oxidation, nitration, phosphorylation or C-ter-
minal truncation [10-13], could contribute to α-synuclein
dysfunction and neuropathology in sporadic PD. The
appearance of some of these modifications correlates well
with neuronal loss and/or pathology in sporadic PD
brains [11-13]. Furthermore, the exact role of Lewy bodies
in dopaminergic neuronal degeneration in PD remains
enigmatic. Therefore, clarifying the mechanisms underly-
ing  α-synuclein-induced dopaminergic neurodegenera-
tion in vivo is critical to understanding the pathogenesis of
familial and sporadic PD.
It is now clear from studies of transgenic mouse models
that α-synuclein pathogenic mutations induce neuronal
dysfunction and degeneration through a toxic gain-of-
function mechanism [14-16]. A number of transgenic
mice have been created that express wild-type or mutant
human α-synuclein in neurons from an array of different
heterologous promoter elements. These include the
broadly expressing mouse prion protein, mouse Thy-1
and human platelet-derived growth factor-β promoters
[17-23], or the catecholaminergic-specific rat tyrosine
hydroxylase (TH) promoter [24-27]. A wide range of α-
synuclein-related neurological phenotypes have been
described in these mouse models that resemble some fea-
tures of PD, such as behavioral motor deficits, neuronal
loss, reduced striatal dopamine levels, and the formation
of filamentous and non-filamentous α-synuclein-positive
inclusions or aggregates. Many of these phenotypes, how-
ever, are not usually observed in the same mouse model.
The most severe phenotypes tend to be observed with
expression of the A53T variant whereas the wild-type pro-
tein is only ever rarely toxic to neurons [15,17,19].
Despite the plethora of α-synuclein mouse models that
have been created, only very few of these exhibit a loss of
nigral dopaminergic neurons, and in general this neuro-
nal loss is not progressive or robust [26,28]. Therefore, α-
synuclein mouse models do not currently exist that relia-
bly recapitulate essential features of PD especially the loss
of nigral dopaminergic neurons, the neuropathological
hallmark of the disease. Thus, there is a requirement for
the development of new α-synuclein transgenic mouse
models that can faithfully recapitulate the dysfunction of
the nigrostriatal dopaminergic pathway in PD. Such mod-
els may arise through improvements in transgenic tech-
nology to increase transgene expression levels and
dopaminergic neuronal specificity, as well as through the
identification of more toxic α-synuclein pathogenic vari-
ants. A combination of these approaches could prove to
be advantageous in developing faithful α-synuclein
mouse models of PD.
Recent studies have highlighted the pathophysiological
significance of C-terminally truncated α-synuclein spe-
cies. Most recently, C-terminal truncation variants, includ-
ing αSyn119, αSyn122 and αSyn123, have been detected
in brain tissue from human PD cases and α-synucleinMolecular Neurodegeneration 2009, 4:34 http://www.molecularneurodegeneration.com/content/4/1/34
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transgenic mice, and were found to be enriched in Lewy
bodies [13,29]. Moreover, in vitro studies demonstrate
that human α-synuclein lacking the C-terminal 20 or 30
amino acids (αSyn120 or αSyn130) assemble more read-
ily into filaments resembling the α-synuclein filaments
observed in Lewy bodies [13,29-31]. Disease-associated
mutations in α-synuclein promote the accumulation of
these truncated filaments compared to the wild-type pro-
tein, and C-terminally truncated species can enhance the
aggregation of wild-type α-synuclein at low substoichio-
metric ratios suggestive of a seeding capacity [13,29,31].
Therefore, C-terminal truncations of α-synuclein could
potentially advance disease progression or propagation
through promoting the pathological aggregation and
accumulation of α-synuclein. At this juncture, however,
the role of C-terminally truncated α-synuclein species in
the pathogenesis of PD is poorly understood. To further
understand the pathophysiological significance of C-ter-
minally truncated α-synuclein species, transgenic mice
have recently been developed that express wild-type
αSyn120 or A53T mutant αSyn130 truncation variants
from the rat TH promoter [25,26]. Collectively, these mice
exhibit filamentous and non-filamentous α-synuclein-
positive aggregates, deficits in locomotion, reduced stri-
atal dopamine levels, and in the A53T-αSyn130 model a
developmental loss of TH-positive nigral neurons and stri-
atal nerve terminals.
Prior to the publication of these α-synuclein truncation
models, we set out to develop a collection of transgenic
mice capable of producing robust expression of human α-
synuclein variants selectively in neurons of the nigrostri-
atal dopaminergic pathway. Encouraged by the promising
neurodegenerative phenotype exhibited by conditional
transgenic mice expressing a polyglutamine-expanded
huntingtin protein [32], we chose to create similar condi-
tional transgenic mice through gene targeting of a Cre-
loxP-based transgene cassette at the ROSA26 genomic
locus to express E46K or A53T mutant human α-synu-
clein, or the putative pathogenic C-terminal truncation,
αSyn119, in a Cre recombinase-dependent manner. It is
worth noting that transgenic mouse models expressing
E46K α-synuclein do not currently exist, and that previous
α-synuclein truncation models rely upon artificial trunca-
tions (αSyn120,  αSyn130) [25,26] rather than trunca-
tions associated with disease pathology (αSyn119) [13].
Here, we combine conditional transgenic technology with
new pathological variants of α-synuclein to evaluate the
effects of expressing these α-synuclein variants directly in
nigrostriatal pathway dopaminergic neurons.
Results
Development of Cre-loxP Conditional Transgenic Mice for 
Human α-Synuclein Variants
To develop new α-synuclein mouse models of PD, our
strategy was to create conditional transgenic mice that
selectively express pathological human α-synuclein vari-
ants in dopaminergic neurons of the nigrostriatal path-
way. Therefore, conditional transgenic mice were created
that express human A53T or E46K α-synuclein or C-termi-
nally truncated αSyn119 variants from the endogenous
murine ROSA26 promoter in a Cre recombinase-depend-
ent manner; hereafter referred to as ROSA26-αSyn mice
(Fig. 1A). In these models, a conditional cassette contain-
ing an α-synuclein transgene immediately preceded by a
loxP-flanked transcriptional termination sequence (neo-
tpA), has been targeted to the murine ROSA26 locus
through homologous recombination [33,34]. Hence,
expression of the α-synuclein transgene is driven by the
ubiquitous, neuronal-selective murine ROSA26 promoter
in discrete neuronal populations following Cre-mediated
excision of the neo-tpA cassette (Fig. 1A). Following suc-
cessful germ line transmission from chimeric mice for
each line, the resulting heterozygous progeny (ROSA26-
αSyn+/-, where + denotes the transgene) were intercrossed
and analyzed by Southern blot to confirm correct target-
ing of the transgene at the ROSA26 locus (Fig. 1B). In gen-
eral, heterozygous and homozygous ROSA26-αSyn mice
are viable and fertile, exhibit normal survival, and mani-
fest no gross behavioral or phenotypic abnormalities.
To induce conditional α-synuclein transgene expression, a
two step breeding strategy was developed with either TH-
Cre or nestin-Cre transgenic mice to derive homozygous
ROSA26-αSyn+/+  mice with or without Cre expression
(Fig. 1C). TH-Cre mice display Cre expression and activity
restricted to central catecholaminergic neuronal popula-
tions within the substantia nigra pars compacta, ventral
tegmental area, locus ceruleus, olfactory bulb, hypotha-
lamic nuclei, and superior cervical ganglia [35]. Nestin-
Cre mice show widespread expression of Cre activity in
neuronal and glial cells throughout the brain [36].
Homozygous ROSA26-αSyn+/+  mice were first crossed
with heterozygous ROSA26-αSyn+/-/TH-Cre or ROSA26-
αSyn+/-/nestin-Cre mice in order to eventually produce
homozygous ROSA26-αSyn+/+/TH-Cre or ROSA26-αSyn+/
+/nestin-Cre mice and their non-floxed ROSA26-αSyn+/+
littermate controls at an expected frequency of 25% per
genotype per litter (Fig. 1C). We notice however that pass-
ing the Cre transgene through the germline in this final
breeding step results in germline excision of the neo-tpA
cassette for one of the transgenic alleles in 100% of the
progeny from crosses with nestin-Cre and ~50% of the
progeny from crosses with TH-Cre i.e. ROSA26-αSyn+/flox/
Cre (Fig. 1C, D). This produces homozygous mice with
conditional transgene expression from one allele but
widespread, unrestricted expression from the opposite
allele. This was unexpected since expression of Cre trans-
genes in these mice is considered to be largely restricted to
CNS tissues but they also appear to exhibit some activity
in the germline in our mice. Thus, we were restricted to
producing cohorts of heterozygous ROSA26-αSyn+/-/nes-Molecular Neurodegeneration 2009, 4:34 http://www.molecularneurodegeneration.com/content/4/1/34
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Generation of Cre-loxP Conditional α-Synuclein Transgenic Mice Figure 1
Generation of Cre-loxP Conditional α-Synuclein Transgenic Mice. (A) Gene targeting strategy for generating condi-
tional ROSA26-αSyn transgenic mice. Human α-synuclein cDNAs were placed downstream of a loxP-flanked cassette contain-
ing a neomycin resistance gene (neo) and a triple transcriptional termination sequence (tpA). The entire neo-tpA-αSyn 
conditional transgene cassette is situated adjacent to the endogenous ROSA26 promoter. Following Cre-mediated excision of 
the neo-tpA cassette, the α-synuclein transgene is expressed from the adjacent ROSA26 promoter. ROSA26-αSyn mice were 
genotyped using the indicated PCR primers P1, P2 and P3. Primers P1/P3 produce a wild-type band of ~500 bp whereas prim-
ers P1/P2 produce a transgenic band of ~250 bp. Following Cre-mediated excision, primers P1/P3 can also amplify a ~1.5 kb 
band from the recombined transgenic allele. SA, splice acceptor; pA, polyadenylation sequence. (B) Southern blot analysis of 
EcoRV-digested tail genomic DNA derived from either wild-type (-/-), heterozygous (+/-) or homozygous (+/+) ROSA26-
αSyn119 mice. Blots were hybridized with a [32P]-labeled DNA probe as indicated in (A). The probe detects the wild-type 
allele at ~11 kb and the transgenic allele at ~3.8 kb owing to an additional EcoRV site in the neo gene, as indicated. (C) Breeding 
strategy to produce floxed ROSA26-αSyn119+/+/TH-Cre mice and their non-floxed ROSA26-αSyn+/+ littermates at a frequency 
of 25% per genotype (italics). Notice that homozygous ROSA26-αSyn119+/+/TH-Cre mice (bold) were often produced with a 
germ line deletion (flox) of one allele (ROSA26-αSyn119+/flox/TH-Cre) at a ratio of 1:1 (+/+ to +/flox) following crossing to 
TH-Cre mice. (D) PCR genotyping strategy for ROSA26-αSyn119/TH-Cre mice using primers P1, P2 and P3 to distinguish the 
transgenic allele (Tg, ~250 bp, P1+P2), wild-type allele (WT, ~500 bp, P1+P3), or the transgenic allele following germline dele-
tion of the neo-tpA cassette (Tgflox, ~1.5 kb, P1+P3).
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tin-Cre mice but could successfully produce homozygous
ROSA26-αSyn+/+/TH-Cre mice following screening and
elimination of mice with germline excision of the neo-tpA
cassette (Fig. 1C, D). Collectively, we have created an
important resource of conditional transgenic mice capa-
ble of expressing A53T, E46K or C-terminally truncated
human  α-synuclein from the endogenous murine
ROSA26 promoter in a Cre recombinase-dependent man-
ner.
Cre-Dependent Expression of Human A53T α-Synuclein 
and αSyn119
We next sought to verify that α-synuclein transgene
expression in these mice can be induced in a Cre-depend-
ent manner. Protein extracts were prepared from brain tis-
sue of 10 month-old floxed ROSA26-αSyn/Cre mice and
their non-floxed ROSA26-αSyn littermates followed by
Western blot analysis with human-specific α-synuclein
antibodies. Human αSyn119 expression is confirmed in
brain regions with TH-positive neurons or nerve terminals
including the olfactory bulb, striatum, cerebral cortex and
ventral midbrain of floxed homozygous ROSA26-
αSyn119+/+/TH-Cre mice that is completely absent from
non-floxed littermate mice (Fig. 2A). Similarly, the expres-
sion of A53T human α-synuclein is confirmed in brain
regions with nestin-positive neurons from floxed hetero-
zygous ROSA26-αSyn-A53T+/-/nestin-Cre mice that is
absent from the brains of their non-floxed littermate mice
(Fig. 2A). Thus, both A53T α-synuclein and αSyn119
transgenes are expressed in a Cre-dependent manner in
these mice. The E46K α-synuclein transgenic mice were
not characterized further in this study.
To compare the expression level of human αSyn119 in the
ROSA26-αSyn mice with endogenous α-synuclein, pro-
teins extracted from various brain regions of 10 month-
old ROSA26-αSyn119/Cre mice and their non-floxed lit-
termates were analyzed by Western blotting with the α-
synuclein antibody, Syn-1. αSyn119 is expressed at less
than 10% of the levels of endogenous α-synuclein in these
brain regions (Fig. 2B). This is perhaps not surprising
since αSyn119 is expressed selectively in most TH-positive
catecholaminergic neurons in these brain regions whereas
endogenous  α-synuclein is known to be expressed
broadly within many neuronal populations throughout
the brain [37]. It is possible to observe a doubling of α-
Syn119 expression between heterozygous and
homozygous floxed ROSA26-αSyn119/TH-Cre mice as
expected (Fig. 2B). We could also confirm a broader dis-
tribution and higher levels of αSyn119 in ROSA26-
αSyn119+/-/nestin-Cre mice compared to ROSA26-
αSyn119+/+/TH-Cre mice reflecting the widespread distri-
bution and greater number of nestin-positive neurons
compared to the more restricted TH-positive catecho-
laminergic neuronal population in each brain region (Fig.
2B). A small proportion of truncated endogenous α-synu-
clein could also be detected in forebrain regions from con-
trol ROSA26-αSyn119+/+ mice that express the highest
levels of endogenous α-synuclein (Fig. 2B), as noted pre-
viously [13]. It was not possible to directly compare the
expression level of human A53T α-synuclein with endog-
enous α-synuclein in the ROSA26-αSyn-A53T/Cre mice
since these proteins co-migrate and human α-synuclein
expression does not appreciably influence the total level
of α-synuclein detectable using the Syn-1 antibody (data
not shown).
Finally, we compared the expression level of A53T α-synu-
clein in our ROSA26-αSyn mice to a well-characterized
mouse prion promoter (mo.PrP)-based A53T human α-
synuclein neurodegenerative mouse model [19,38].
Despite the lack of obvious substantia nigra pathology in
this mo.PrP-A53T mouse model, it is possible to detect
more prominent α-synuclein expression in the ventral
midbrain by Western blotting with the human-specific
LB509 antibody compared to the ROSA26-αSyn-A53T
mice with transgene expression directed to either TH-pos-
itive or nestin-positive neurons (Fig. 2C). This finding
most likely relates to the relatively small contribution of
TH-positive neurons to the total number of neurons
within the ventral midbrain region which is highlighted
by the observation that heterozygous ROSA26-αSyn-A53T+/
-/nestin-Cre mice produced far greater transgene expres-
sion than homozygous  ROSA26-αSyn-A53T+/+/TH-Cre
mice (Fig. 2C). Greater α-synuclein expression observed
in the mo.PrP-A53T transgenic mice compared to the
ROSA26-αSyn-A53T+/-/nestin-Cre mice most likely relates
to differences in the strength of the ROSA26 and mo.PrP
promoters and/or transgene copy number, both of which
are considered to be higher in the mo.PrP-A53T mice [19].
Due to the low level of transgene expression in the
ROSA26-αSyn/Cre mice it was not possible to reliably
demonstrate the selective neuronal distribution pattern of
human α-synuclein above background by immunohisto-
chemical methods with currently available human-spe-
cific α-synuclein antibodies or the Syn-1 antibody (data
not shown). It was also not possible to observe the pres-
ence of α-synuclein pathological inclusions or aggregates
in the substantia nigra of these mice up to 10 months of
age (data not shown). Collectively, this data demonstrates
that the ROSA26-αSyn mice express human αSyn119 or
human A53T α-synuclein in a Cre-dependent manner but
at lower levels than those of endogenous, murine α-synu-
clein or A53T α-synuclein expressed in mo.PrP transgenic
mice.
Lack of Nigral Dopaminergic Neuronal Degeneration in α-
Synuclein Transgenic Mice
To determine whether the expression of human αSyn119
or A53T α-synuclein in the ROSA26-αSyn/Cre mice could
contribute to the degeneration of nigrostriatal dopamin-
ergic neurons with age, we generated suitably-sizedMolecular Neurodegeneration 2009, 4:34 http://www.molecularneurodegeneration.com/content/4/1/34
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cohorts of aged floxed and non-floxed mice. In particular,
we generated αSyn119 or A53T α-synuclein mice crossed
with TH-Cre (ROSA26-αSyn+/+/TH-Cre) or nestin-Cre
(ROSA26-αSyn+/-/nestin-Cre) transgenic mice and their
non-floxed age-matched littermates (ROSA26-αSyn+/- or
ROSA26-αSyn+/+ mice). It is anticipated that TH-Cre and
nestin-Cre mice would direct transgene expression in the
vast majority of nigral dopaminergic neurons in the
ROSA26-αSyn/Cre mice [35,36]. Mice were aged to 10–12
months and the numbers of TH-positive and Nissl-posi-
tive neurons in the substantia nigra pars compacta were
counted using unbiased stereological methods (Fig. 3A).
At this age, we fail to observe a significant loss of nigral
dopaminergic neurons or Nissl-positive neurons due to
human  αSyn119 or A53T α-synuclein expression (Fig.
3A–E). In general, we do not observe alterations in the
survival of the ROSA26-αSyn119/Cre mice up to 18
months of age. It is not possible to conclude whether or
not the αSyn119 protein has pathophysiological proper-
ties since comparable mice expressing pathogenic A53T α-
Cre-Dependent Human α-Synuclein Expression in ROSA26-αSyn Mice Figure 2
Cre-Dependent Human α-Synuclein Expression in ROSA26-αSyn Mice. (A) Cre-dependent expression of α-synu-
clein variants. Protein extracts (50 μg) derived from distinct brain regions of 10 month-old ROSA26-αSyn119+/+/TH-Cre mice 
and their ROSA26-αSyn119+/+ littermate controls were probed with the human-specific α-synuclein antibody, Syn204, with 
actin and TH antibodies as controls. HEK-293T cells expressing human αSyn119 were used as a positive control. Equivalent 
proteins derived from ROSA26-αSyn-A53T+/-/nestin-Cre mice and their ROSA26-αSyn-A53T+/- littermates were probed with 
human-specific α-synuclein antibody, LB509, and actin antibody. HEK-293T cells expressing human αSyn-A53T were used as a 
positive control. (B) Comparison of human αSyn119 expression with endogenous α-synuclein. Proteins (50 μg) derived from 
distinct brain regions of 10 month-old ROSA26-αSyn119+/-/TH-Cre, ROSA26-αSyn119+/+/TH-Cre, ROSA26-αSyn119+/-/nes-
tin-Cre and their ROSA26-αSyn119+/+ littermate controls were probed with α-synuclein antibody, Syn-1, to detect endog-
enous mouse (ms) α-synuclein and human αSyn119 expression. (C) Comparison of human A53T α-synuclein expression in 
ROSA26-αSyn-A53T mice and mouse prion promoter (mo.PrP) A53T-αSyn transgenic mice. Proteins extracted from ventral 
midbrain tissue of adult ROSA26-αSyn-A53T mice (50 μg) and mo.PrP-A53T mice (5 μg) were probed with LB509 antibody or 
actin antibody as a loading control. HEK-293T cells expressing human αSyn-A53T were used as a positive control.
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Lack of Nigral Dopaminergic Neuronal Degeneration in ROSA26-αSyn Mice Figure 3
Lack of Nigral Dopaminergic Neuronal Degeneration in ROSA26-αSyn Mice. Stereological analysis of TH-positive 
and Nissl-positive neurons in the substantia nigra pars compacta of male ROSA26-αSyn mice with or without Cre expression. 
(A) Example of immunohistochemical staining for TH with Nissl counterstain on coronal midbrain sections highlighting the sub-
stantia nigra region from 12 month-old ROSA26-αSyn119+/+/TH-Cre mice and their ROSA26-αSyn119+/+ littermate controls. 
(B-E) Stereological analysis revealing a normal number of TH-positive and Nissl-positive neurons in the substantia nigra pars 
compacta (SNpc) of 10–12 month-old ROSA26-αSyn119+/-/nestin-Cre (B), ROSA26-αSyn119+/+/TH-Cre (C), ROSA26-αSyn-
A53T+/-/nestin-Cre (D) and ROSA26-αSyn-A53T+/+/TH-Cre (E) mice compared to their age-matched non-floxed ROSA26-
αSyn littermates (Cre -). Data are expressed as the mean ± SEM (n = 4–6 mice per genotype). There are no significant differ-
ences (p > 0.05) between genotypes following statistical analysis by unpaired, two-tailed Student's t test.Molecular Neurodegeneration 2009, 4:34 http://www.molecularneurodegeneration.com/content/4/1/34
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synuclein at identical levels in the same neurons also
failed to influence dopaminergic neuronal viability in
these mice.
Reduced Striatal Dopamine Induced by αSyn119 
Expression in Catecholaminergic Neurons
To determine whether the expression of human αSyn119
in nigral dopaminergic neurons leads to nigrostriatal neu-
ronal dysfunction, we monitored the levels of striatal
dopamine and its metabolites in aged ROSA26-αSyn119/
Cre mice and their non-floxed littermate control mice by
HPLC. No differences in the levels of striatal dopamine or
its metabolites, 3,4-dihydroxyphenylacetic acid (DOPAC)
and homovanillic acid (HVA), are observed in hetero-
zygous ROSA26-αSyn119+/-/nestin-Cre mice compared to
their non-floxed littermates at 12–13 months of age (Fig.
4A, B). However, in homozygous ROSA26-αSyn119+/+/
TH-Cre mice with an approximate doubling of αSyn119
expression in TH-positive dopaminergic neurons, we
observe a significant marked reduction in the levels of stri-
atal dopamine (~32%), DOPAC (~46%) and HVA
(~33%) compared to their non-floxed ROSA26-
αSyn119+/+ littermates at 10–11 months of age (Fig. 4C,
D). This effect on the nigrostriatal dopaminergic system is
specific since the levels of striatal 5-hydroxytryptamine (5-
HT) in these ROSA26-αSyn119+/+/TH-Cre mice are nor-
mal (Fig. 4D). No further alterations in dopamine levels
in other regions of the brain are observed in these mice,
including the olfactory bulb, cerebral cortex and prefron-
tal cortex (data not shown). Furthermore, striatal
dopamine turnover in the ROSA26-αSyn119/Cre mice is
also normal (data not shown). Taken together, this data
demonstrates that the expression of human αSyn119 in
TH-positive catecholaminergic neurons leads to a reduc-
tion in striatal dopamine content in the absence of nigral
dopaminergic neuronal loss. This effect would appear to
be dependent on transgene dosage since the reduced
expression of αSyn119 in heterozygous ROSA26-
αSyn119+/-/nestin-Cre mice fails to induce deficits in stri-
atal dopamine levels. Alternatively, this effect could
potentially relate to mosaic expression of Cre recombi-
nase in nigral dopaminergic neurons of TH-Cre and nes-
tin-Cre transgenic mice. Our data suggest that human
αSyn119 may be of pathophysiological relevance in vivo.
Neurochemical Alterations in αSyn119 Transgenic Mice
To further evaluate the potential pathophysiological
effects of αSyn119 expression in the brain, the levels of
the neurotransmitters norepinephrine (NE) and 5-HT
were monitored in the olfactory bulb, cerebral cortex, pre-
frontal cortex, striatum and brainstem. A significant
increase in the level of NE in the striatum (Fig. 5A) and 5-
HT in the prefrontal cortex (Fig. 5B) is observed in
homozygous ROSA26-αSyn119+/+/TH-Cre mice com-
pared to their non-floxed littermates at 10–11 months of
age. NE and 5-HT levels in these brain regions are normal
in heterozygous ROSA26-αSyn119+/-/nestin-Cre mice at
12–13 months of age suggesting that the alterations in
neurotransmitter levels are specific to the homozygous
ROSA26-αSyn119+/+/TH-Cre mice (data not shown).
Thus, αSyn119 expression in TH-positive catecholaminer-
gic neurons induces additional subtle neurochemical
alterations in vivo.
Discussion
Here, we describe the development and evaluation of con-
ditional transgenic mice expressing human α-synuclein
pathological variants in dopaminergic neurons of the
nigrostriatal pathway from the endogenous ROSA26 pro-
moter. Our investigations have focused on the potential
contribution of two pathologic variants, A53T mutant α-
synuclein and C-terminally truncated αSyn119, to the
normal integrity and function of nigral dopaminergic
neurons with age. Our studies demonstrate that A53T α-
synuclein and αSyn119 are expressed in a Cre recombi-
nase-dependent manner in these ROSA26-αSyn mice. We
show that neither A53T α-synuclein nor αSyn119 expres-
sion in mice aged for up to 12 months is sufficient to
induce the degeneration of nigral dopaminergic neurons.
However, we demonstrate that the expression of αSyn119
in nigral dopaminergic neurons for up to 12 months in
this mouse model causes a marked reduction in the levels
of striatal dopamine and its metabolites in addition to
other subtle neurochemical alterations. Thus, at ages up to
12 months we observe nigrostriatal dopaminergic path-
way dysfunction in the absence of frank neuronal loss.
Further deficits in nigrostriatal dopaminergic function
may be revealed in these mice with advanced age. The
ROSA26-αSyn mice therefore represent a useful model of
striatal dopamine depletion and could provide a potential
presymptomatic model of PD perhaps representative of
the earliest derangements in dopaminergic neuronal func-
tion observed prior to neuronal loss.
Our data suggest that the C-terminally truncated α-synu-
clein variant, αSyn119, is of pathophysiological relevance
in vivo. The expression of αSyn119 in nigral TH-positive
dopaminergic neurons precipitates striatal dopamine loss
without compromising dopaminergic neuronal viability.
αSyn119, together with αSyn122 and αSyn123, are nor-
mally present in mammalian brain at low levels but are
enriched as soluble and aggregated species in Lewy body-
positive PD and DLB brains and in transgenic mouse
brains expressing human A53T α-synuclein [13,29]. Fur-
thermore, disease-associated mutations in α-synuclein
promote the accumulation of αSyn119 and other trunca-
tion species compared to the wild-type protein in neural
cell lines and α-synuclein transgenic mice [13,29]. Further
supporting the pathogenicity of truncated αSyn119 and
related species, in vitro studies demonstrate that C-termi-
nally truncated α-synuclein variants fibrillize and aggre-
gate more readily than the full-length protein and canMolecular Neurodegeneration 2009, 4:34 http://www.molecularneurodegeneration.com/content/4/1/34
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seed the aggregation of full-length α-synuclein [13,29-
31]. The mechanism through which α-synuclein C-termi-
nal truncations arise is not known. α-Synuclein can be
proteolytically processed at its C-terminus via a number of
proteases in vitro, including cathepsin D and calpain I, but
as yet none of these proteases have been shown to specif-
ically generate the αSyn119 variant [39-42]. However,
αSyn119 expression has been demonstrated in vivo and
this variant accumulates in diseased brain tissue [13,29].
The normal and pathophysiological mechanism responsi-
ble for the generation of αSyn119 and similar truncation
variants in vivo remains to be clarified.
αSyn119 Expression in Catecholaminergic Neurons Leads to a Reduction of Striatal Dopamine and its Metabolites Figure 4
αSyn119 Expression in Catecholaminergic Neurons Leads to a Reduction of Striatal Dopamine and its Metab-
olites. Analysis of striatal biogenic amines in ROSA26-αSyn119 mice by HPLC with electrochemical detection. The level of 
dopamine (A, C), or the dopamine metabolites, DOPAC and HVA, and 5-HT (B, D) were measured by HPLC in striatal tissue 
from (A, B) 12–13 month-old female ROSA26-αSyn119+/-/nestin-Cre mice (Cre +) and their ROSA26-αSyn119+/- littermate 
controls (Cre -) and from (C, D) 10–11 month-old female ROSA26-αSyn119+/+/TH-Cre mice (Cre +) and their ROSA26-
αSyn119+/+ littermate controls (Cre -). The concentration of each biogenic amine is expressed as ng per mg of protein, and 
data represent the mean ± SEM (n = 7–9 mice for nestin-Cre and n = 5–6 mice for TH-Cre). Significant differences between 
Cre- and Cre + genotypes were determined following statistical analysis by unpaired, two-tailed Student's t test (*p < 0.05, **p 
< 0.01).
A B
C
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Our data in the ROSA26-αSyn mice provides the first in
vivo demonstration of a pathophysiological effect of the
disease-associated  αSyn119 species on the nigrostriatal
dopaminergic pathway. It is not yet clear how the expres-
sion of αSyn119 in dopaminergic neurons produces defi-
cits in striatal dopamine levels in the absence of frank
neuronal loss. αSyn119 could potentially induce the dys-
function or degeneration of striatal dopaminergic nerve
terminals without compromising the integrity of the neu-
ronal soma. At the cellular level, αSyn119 could impair
pre-synaptic dopaminergic nerve terminals through the
accumulation of submicroscopic toxic oligomers or aggre-
gates [13,29], or could potentially sensitize nerve termi-
nals to secondary insults such as oxidative and nitrosative
stress that accumulate with age [43]. Future analyses of
these mice will aim to clarify the mechanism through
which  αSyn119 could potentially act at nigrostriatal
dopaminergic nerve terminals. The effects of αSyn119
expression in vivo are reminiscent to those of αSyn120
expressed in transgenic mice from the rat TH promoter on
an α-synuclein null background [25]. αSyn120 transgenic
mice exhibit a reduction in striatal dopamine and HVA
levels that are first evident between 1–3 months but do
not worsen up to 12 months of age [25]. Accompanying
these alterations are late-onset motoric deficits and the
formation of pathological α-synuclein inclusions. A
caveat of this mouse model is that the αSyn120 truncated
species has not yet been observed in vivo in brain tissue
and may therefore represent a non-physiological trun-
cated α-synuclein species [13]. Furthermore, the αSyn120
mice were generated on an α-synuclein null background
which complicates the interpretation of their phenotype.
Nevertheless, the ROSA26-αSyn119 mice and the
αSyn120 transgenic mice suggest that C-terminal trunca-
tion of α-synuclein could represent a pathophysiological
process during the development and/or propagation of
PD that potentially contributes to the dysfunction of the
nigrostriatal dopaminergic pathway.
The ROSA26-αSyn mice offer an important resource for
modeling various aspects of PD. These mice allow the
expression of disease-associated α-synuclein variants
selectively in nigrostriatal pathway dopaminergic neurons
in order to evaluate their potentially pathogenic affects
with age. Transgene expression in these mice is driven by
the well-characterized neuronal-specific, endogenous
murine ROSA26 promoter in a Cre-dependent manner
[33,34,44]. This system permits the expression of α-synu-
clein variants in virtually any neuronal population in the
brain depending upon the availability of suitable Cre
driver lines. Conceivably, these ROSA26-αSyn mice could
also be used to model other α-synucleinopathies, such as
DLB, by directing transgene expression to neurons of the
forebrain. A particularly attractive feature of these
ROSA26-αSyn mice is that one can directly compare the
effects of different pathological variants of the α-synuclein
protein since variants are expressed at equivalent levels
from the same stable promoter at identical copy number
in the same neurons. This provides a clear advance over
conventional transgenesis where individual founder lines
can often produce marked differences in transgene expres-
sion levels and expression patterns due to the effects of
genomic integration site, epigenetic modifications and
transgene copy number. Of note, there are no known phe-
notypes associated with disruption of the ROSA26
genomic locus [33,44]. However, an obvious caveat of the
Neurochemical Alterations Caused by αSyn119 Expression  in Catecholaminergic Neurons Figure 5
Neurochemical Alterations Caused by αSyn119 
Expression in Catecholaminergic Neurons. Analysis of 
biogenic amines in discrete brain regions of ROSA26-
αSyn119 mice by HPLC with electrochemical detection. The 
level of NE (A) and 5-HT (B) were measured by HPLC in 
olfactory bulb, cerebral cortex, prefrontal cortex, striatum 
and brainstem tissues of 10–11 month-old female ROSA26-
αSyn119+/+/TH-Cre mice (Cre +) and their ROSA26-
αSyn119+/+ littermate controls (Cre -). The concentration of 
NE and 5-HT is expressed as ng per mg of tissue, and data 
represent the mean ± SEM (n = 5–7 mice per genotype). Sig-
nificant differences between Cre - and Cre + genotypes were 
determined following statistical analysis by unpaired, two-
tailed Student's t test (*p < 0.05).
A
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ROSA26-αSyn mice is reduced transgene expression since
only one to two transgene copies can be accommodated at
the ROSA26 locus. Using the ROSA26-αSyn mice it is pos-
sible to co-express two pathological α-synuclein variants
from opposite alleles at equivalent levels in the same neu-
rons to investigate how they may interact to precipitate
pathology or compromise neuronal viability. This feature
allows one to examine, for example, whether αSyn119
expression can seed and accelerate the aggregation of the
full-length  α-synuclein variants, A53T or E46K, in
dopaminergic neurons in vivo. Another useful feature of
the ROSA26-αSyn mice is that they are ideally suited for
investigating potential gene-environment interactions
with dopamine neuron-specific toxins such as MPTP [45]
since α-synuclein expression can be directed selectively to
nigrostriatal pathway dopaminergic neurons using the
TH-Cre driver line. In this scenario, one can directly com-
pare the potential differential interaction of dopaminergic
toxins with various pathogenic α-synuclein variants.
Importantly, we have made these ROSA26-αSyn mice
available as a unique resource to the PD research commu-
nity by distribution through The Jackson Laboratory. The
ROSA26-αSyn mice provide a useful and unique tool for
evaluating the age-related effects of expressing α-synu-
clein pathogenic variants in neurons in vivo that will hope-
fully provide important insight into the molecular
mechanisms underlying the pathogenesis of PD and DLB.
Materials and methods
Generation and Breeding of Conditional α-Synuclein 
Transgenic Mice
Human α-synuclein variants (E46K, A53T or 1–119) were
targeted to the ROSA26 genomic locus in 129/SvJ embry-
onic stem (ES) cells as described [34]. Briefly, α-synuclein
cDNAs were subcloned into XhoI and NotI sites of accep-
tor plasmid pBigT thereby placing the transgene down-
stream of a loxP-flanked neo-tpA transcriptional
termination cassette [34]. The entire neo-tpA-α-synuclein
conditional transgene was excised and inserted into tar-
geting plasmid pROSA26PA via PacI and AscI sites [34].
The final pROSA26PA-αSyn construct was linearized with
KpnI, gel purified with GELase reagent (Epicenter, Madi-
son, WI) and used for electroporation of mouse 129/SvJ
ES cells. Following G418 selection, at least six correctly
targeted ES cell clones were identified by PCR and South-
ern blot analysis as described [33,34], and two clones
were microinjected into C57BL/6J mouse blastocysts to
derive chimeric mice. Four to six chimeras were bred with
C57BL/6J mice for each targeting construct with at least
one chimeric mouse producing germline transmission of
the correctly targeted allele to F1 progeny. ES cell selec-
tion, blastocyst microinjection and chimera breeding was
conducted by the University of Cincinnati Gene-Targeted
Mouse Service. F1 heterozygous mice were routinely iden-
tified by PCR of tail genomic DNA with primers: P1, 5'-
aaagtcgctctgagttgttat-3'; P2, 5'-gcgaagagtttgtcctcaacc-3'; P3,
5'-ggagcgggagaaatggatatg-3'; producing a ~500 bp product
from the WT allele and a ~250 bp product from the trans-
genic allele [33,34]. Following intercrossing of F1 hetero-
zygous mice, mice were further analyzed by Southern blot
to verify correct targeting of the transgene at the ROSA26
locus.
ROSA26-αSyn mice were maintained as 129/SvJ  and
C57BL/6J hybrids through backcrossing to C57BL/6J mice
for 1–2 generations and then intercrossing of hetero-
zygous progeny. TH-Cre [35] and nestin-Cre [36] trans-
genic mice were maintained on a C57BL/6J background.
Nestin-Cre transgenic mice (stock number 003771) were
obtained from The Jackson Laboratory (Bar Harbor, ME).
To generate cohorts of mice for aging, heterozygous
ROSA26-αSyn+/- mice were crossed with each hemizygous
Cre line, and the F1 ROSA26-αSyn+/-/Cre progeny were
further crossed with homozygous ROSA26-αSyn+/+ mice
to produce F2 mice. The F2 mice produced from these
crosses on a mixed 129/SvJ and C57BL/6J hybrid back-
ground were used throughout this study. Age-matched
ROSA26-αSyn+/- or, +/+ littermates without Cre were used as
controls. Cre transgenes were genotyped by an established
PCR protocol with the primers 5'-AAATGTTGCTGGAT-
AGTTTTTACTGC-3' and 5'-GGAAGGTGTCCAATTTACT-
GACCGTA-3' to produce a 300 bp transgenic fragment
[35]. Adult hemizygous PrP-A53T-αSyn transgenic mice
[19] were kindly provided by Dr. Michael K. Lee (Johns
Hopkins University). All mice were housed and treated in
strict accordance with the National Institutes of Health
Guide for the Care and Use of Laboratory Animals. Mice were
maintained in a pathogen-free facility and exposed to a 12
h light/dark cycle with food and water provided ad libitum.
The ROSA26-αSyn mice are available from The Jackson
Laboratory (Bar Harbor, ME; http://www.jax.org); JAX
stock number, 008883 (ROAS26-Syn-A53T), 008886
(ROSA26-Syn-E46K) and 008889 (ROSA26-Syn119).
Western blot analysis
Brain regions, including the olfactory bulb, cerebral cor-
tex, striatum, ventral midbrain, brainstem and cerebel-
lum, from 10 month-old mice were dissected from fresh
brains, homogenized in ice-cold RIPA buffer (50 mM Tris-
HCl, pH 7.4, 150 mM NaCl, 5 mM EDTA, 1% Triton X-
100, 0.1% SDS, 1× Complete Mini protease inhibitor
cocktail [Roche]), and then centrifuged at 20,000 × g for
15 min at 4°C. The RIPA-soluble supernatant fraction was
collected, quantified using BCA reagent (Pierce, Rockford,
IL) with BSA standards, and stored at -80°C. Proteins
(100 μg) were resolved by electrophoresis on 15% SDS-
PAGE gels and transferred to nitrocellulose membranes
(0.2 μm; Biorad). To detect α-synuclein expression, blots
were probed with human-specific mouse monoclonal
antibodies, Syn204 (Cell Signaling Technology) and
LB509 (Zymed), or with the mouse monoclonal Syn-1
antibody (BD Bioscience). Antibodies to tyrosine hydrox-Molecular Neurodegeneration 2009, 4:34 http://www.molecularneurodegeneration.com/content/4/1/34
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ylase (Novus Biologicals) and actin (Sigma) were used to
control for regional dissection and protein loading,
respectively. Lysates derived from HEK-293T cells tran-
siently expressing untagged human α-synuclein (A53T or
Syn119; pcDNA3.1 expression vector [Invitrogen] [19])
served as positive controls for α-synuclein antibodies. To
compare A53T α-synuclein expression in ventral midbrain
tissue from adult mo.PrP-A53T-αSyn mice [19] and
ROSA26-αSyn-A53T/Cre mice, proteins were prepared as
described above and analyzed by Western blotting with
LB509 antibody.
Immunohistochemistry and Stereological Cell Counting
Perfusion-fixed coronal midbrain sections (40-μm) were
cut on a sliding microtome (Microm, Kalamazoo, MI) and
collected free-floating in PBS. Sections were permeabi-
lized and blocked in PBS containing 0.4% Triton X-100
and 4% normal goat serum at room temperature for 30
min. Sections then were incubated in rabbit polyclonal
anti-TH antibody (1:1000; Novus Biologicals, Littleton,
CO) in PBS containing 0.2% Triton X-100 and 2% normal
goat serum overnight at 4°C and washed with PBS con-
taining 0.2% Triton X-100 and 1% normal goat serum.
Next, sections were incubated for 1 hr in biotinylated goat
anti-rabbit antibody (1:1000; Jackson ImmunoResearch,
West Grove, PA) in PBS with 0.2% Triton X-100 and 1.5%
goat serum, washed, and visualized by incubation in
biotin-streptavidin-HRP complex (ABC; Vector Laborato-
ries, Burlingame, CA), followed by incubation with 3,3'-
diaminobenzidine per the manufacturer's instructions
(Sigma). Sections were mounted on glass slides and
allowed to air dry overnight before being counterstained
with Nissl, dehydrated with ethanol, and cover-slipped
for visualization. To evaluate dopaminergic neuronal loss,
unbiased stereological methodology was employed as
described previously [46,47] to count TH-positive and
Nissl-positive neurons in the left and right pars compacta
region of every fourth section throughout the entire mid-
brain region. This method was carried out by using a com-
puter-assisted image analysis system, consisting of an
Axiophot 2 photomicroscope (Carl Zeiss Vision, Hall-
bergmoos, Germany) equipped with a computer-control-
led motorized stage (Ludl Electronics, Hawthorne, NY), a
Hitachi HV C20 video camera, and interfaced with a
Stereo Investigator system (MicroBrightField, Williston,
VT, USA) with optical fractionator probe.
Measurement of Biogenic Amines by HPLC
HPLC with electrochemical detection was used to meas-
ure the concentration of the biogenic amines, dopamine,
3,4-dihydroxyphenylacetic acid (DOPAC), homovanillic
acid (HVA), 5-hydroxytryptamine (5-HT), 5-hydroxyin-
doleacetic acid (5-HIAA) and norepinephrine (NE) in dis-
crete brain regions, as previously described [48]. Female
ROSA26-αSyn/Cre mice and age-matched ROSA26-αSyn
littermate controls were sacrificed by decapitation, brains
were quickly removed and frozen on dry ice, and stored at
-80°C. Striata, prefrontal cortex, cerebral cortex, olfactory
bulb and brainstem were dissected from frozen tissue and
samples were weighed and sonicated in 0.2 ml of 0.1 M
perchloric acid (at 100 μl/mg tissue) containing 0.01%
EDTA and 25 μg/ml 3,4-dihydroxybenzylamine (DHBA,
Sigma) as an internal standard. Following centrifugation
at 15,000 × g for 10 min at 4°C, 20 μl of supernatant was
injected onto a C-18 80 × 4.6 mm column (ESA, Inc
Chelmsford, MA). The mobile phase consisted of 0.1 M
LiH2PO4, 0.85 mM 1-octanesulfonic acid and 10% (v/v)
methanol. The flow rate was kept at 1 ml/min. Biogenic
amines and their metabolites were detected by a 2-chan-
nel Coulochem II electrochemical detector (ESA, Inc.
Chelmsford, MA) with the working electrode kept at 0.7
V. Data were collected and processed using external stand-
ards for respective amines on a EZChrome Elite Client
Workstation (ESA, Inc. Chelmsford, MA). Concentrations
of biogenic amines are expressed as ng per mg protein.
The protein concentrations of tissue homogenates were
measured using BCA reagent (Pierce, Rockford, IL).
Statistical Analysis
Throughout the experiments investigators were blinded to
genotype of the mice. Data represent mean ± S.E.M. from
groups of animals for each genotype. Statistical analysis
for stereology and HPLC assessments between genotypes
were assessed by unpaired, two-tailed Students t test. Dif-
ferences were considered significant when p < 0.05. All sta-
tistical analyses were performed using GraphPad InStat-
version 3 and Prism software (San Diego, CA).
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